Latest From Geneos Therapeutics
Private Company Edition: Venture capital for emerging therapeutics companies in the US and in ex-US regions reached all-time highs in 2018. Also, Alphamab raises $60m Series B, three new VC funds launch and FLX changes its name to RAPT.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced January and February 2019.
- Therapeutic Areas
- North America
- Company Type
- Parent & Subsidiaries
- Geneos Therapeutics
- Senior Management
Niranjan Y Sardesai, PhD, Pres. & CEO
James A Barlow, VP, Head, Operations & Bus. Dev.
- Contact Info
660 West Germantown Pike
Plymouth Meeting, PA 19462
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.